Evidence map›Paper›PMID 26102294›Full record

ArticleCell cycle (Georgetown, Tex.)2015

Role of stress-activated OCT4A in the cell fate decisions of embryonal carcinoma cells treated with etoposide.

Anda Huna, Kristine Salmina, Jekaterina Erenpreisa, Alejandro Vazquez-Martin, Jekabs Krigerts, Inna Inashkina, Bogdan I Gerashchenko, Paul A Townsend, Mark S Cragg, Thomas R Jackson

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. OCT4A and the DNA damage response.Cell cycle (Georgetown, Tex.) · 2015
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 5 countries.

Anda Hunaa Latvian Biomedical Research and Study Center ; Riga, Latvia.
Kristine Salminaa Latvian Biomedical Research and Study Center ; Riga, Latvia.
Jekaterina Erenpreisaa Latvian Biomedical Research and Study Center ; Riga, Latvia.
Alejandro Vazquez-Martina Latvian Biomedical Research and Study Center ; Riga, Latvia.
Jekabs Krigertsa Latvian Biomedical Research and Study Center ; Riga, Latvia.
Inna Inashkinaa Latvian Biomedical Research and Study Center ; Riga, Latvia.
Bogdan I Gerashchenkoa Latvian Biomedical Research and Study Center ; Riga, Latvia.
Paul A Townsendb Institute of Cancer Sciences; Manchester Cancer Research Center; University of Manchester; Manchester Academic Health Science Center ; Manchester , UK.
Mark S Craggc Cancer Sciences Unit; University of Southampton; Faculty of Medicine; General Hospital ; Southampton , UK.
Thomas R Jacksonb Institute of Cancer Sciences; Manchester Cancer Research Center; University of Manchester; Manchester Academic Health Science Center ; Manchester , UK.
Latvian Biomedical Research and Study Centre · LVCancer Research Center · USInstitute of Cancer Research · CAUniversity of Southampton · GB

Funding

Medical Research Council
6 · The paper itself

Abstract

Tumor cellular senescence induced by genotoxic treatments has recently been found to be paradoxically linked to the induction of "stemness." This observation is critical as it directly impinges upon the response of tumors to current chemo-radio-therapy treatment regimens. Previously, we showed that following etoposide (ETO) treatment embryonal carcinoma PA-1 cells undergo a p53-dependent upregulation of OCT4A and p21Cip1 (governing self-renewal and regulating cell cycle inhibition and senescence, respectively). Here we report further detail on the relationship between these and other critical cell-fate regulators. PA-1 cells treated with ETO display highly heterogeneous increases in OCT4A and p21Cip1 indicative of dis-adaptation catastrophe. Silencing OCT4A suppresses p21Cip1, changes cell cycle regulation and subsequently suppresses terminal senescence; p21Cip1-silencing did not affect OCT4A expression or cellular phenotype. SOX2 and NANOG expression did not change following ETO treatment suggesting a dissociation of OCT4A from its pluripotency function. Instead, ETO-induced OCT4A was concomitant with activation of AMPK, a key component of metabolic stress and autophagy regulation. p16ink4a, the inducer of terminal senescence, underwent autophagic sequestration in the cytoplasm of ETO-treated cells, allowing alternative cell fates. Accordingly, failure of autophagy was accompanied by an accumulation of p16ink4a, nuclear disintegration, and loss of cell recovery. Together, these findings imply that OCT4A induction following DNA damage in PA-1 cells, performs a cell stress, rather than self-renewal, function by moderating the expression of p21Cip1, which alongside AMPK helps to then regulate autophagy. Moreover, this data indicates that exhaustion of autophagy, through persistent DNA damage, is the cause of terminal cellular senescence.

Indexed as

Cellular SenescenceStress, PhysiologicalAMP-Activated Protein KinasesAutophagyCell Cycle CheckpointsCyclin-Dependent Kinase Inhibitor p16DNA DamageEtoposideGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansNanog Homeobox ProteinOctamer Transcription Factor-3SOXB1 Transcription FactorsAMP-Activated Protein KinasesCyclin-Dependent Kinase Inhibitor p16EtoposideHomeodomain ProteinsNanog Homeobox ProteinNANOG protein, humanOctamer Transcription Factor-3POU5F1 protein, humanSOX2 protein, humanSOXB1 Transcription Factorscell-fateDNA damageOCT4A/POU5F1p16ink4ap21Cip1p53p62pluripotencyself-renewalsenescencetumor cells

Identifiers

PMID26102294
PMCPMC4825594
OpenAlexW1866485899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.